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ABSTRACT
Patients with the systemic autoimmune diseases Sjögren's syndrome (SS) and systemic lupus
erythematosus (SLE), often have antibodies against the intracellular protein TRIM21/Ro52.
Although the presence of anti-TRIM21/Ro52 autoantibodies is used as a diagnostic tool, the
biological function of TRIM21/Ro52 is still unknown. The aim of this thesis is to provide a better
understanding of the function of TRIM21/Ro52, especially regarding its role in autoimmunity. To
achieve this, TRIM21/Ro52 was studied at a molecular and cellular level in vitro and in vivo. By
using circular dichroism, limited proteolysis, mass spectrometry, ultra-centrifugation, and two-
hybrid experiments, it was shown that TRIM21/Ro52 is a Zn2+ binding protein that forms weak
dimers. These results also confirmed the presence of the predicted secondary structure domains of
TRIM21/Ro52. A RING domain in the N-terminus of TRIM21/Ro52 suggests that
TRIM21/Ro52 is a RING dependent E3 ligase. Through ubiquitination assays, it was shown that
TRIM/Ro52 is indeed an E3 ligase and that the E3 ligase activity of TRIM21/Ro52 was dependent
on the E2 enzymes UbcH5a-c or UbcH6. Furthermore, anti-RING autoantibodies from patients
with SS and SLE blocked the E3 activity of TRIM21/Ro52 in vitro. Since the expression of many
TRIM proteins is induced by interferons, the effect of interferon alpha (IFNα) and virus on
TRIM21/Ro52 expression was investigated. After exposing the cell lines HeLa, Daudi and Raji to
IFNα, TRIM21/Ro52 expression was increased both at the mRNA and protein level. In addition,
TRIM21/Ro52 expression was increased in human peripheral blood mononuclear cells (PBMC)
exposed to inactivated herpes simplex virus. TRIM21/Ro52 was also expressed at a higher level in
PBMCs from patients with SS and SLE than in PBMCs from healthy individuals, which could be
interpreted as an effect of the interferon signature typical of SS and SLE patients. To investigate the
effect of overexpressing TRIM21/Ro52 in B cells, stable transfected cell lines were made and
characterized. B cells overexpressing TRIM21/Ro52 proliferated slower and were more sensitive to
induced cell death; which was in contrast to B cells expressing a TRIM21/Ro52 mutant lacking E3
ligase activity. Thus, TRIM21/Ro52 is involved in regulating proliferation, and activation status, of
B lymphocytes. The intracellular localization of TRIM21/Ro52 was determined by transfecting
HeLa cells with GFP-Ro52 and GFP-Ro52 mutants. Two stretches of amino acids (aa) were found
to be important for the cytoplasmic localization and nuclear import of TRIM21/Ro52. When the
aa 203-248 were deleted, TRIM21/Ro52 entered the nucleus; but the deletion of aa 381-470
prevented the nuclear import of TRIM21/Ro52. In addition, exposure to IFNα and nitric oxide
induced translocation of TRIM21/Ro52 from the cytoplasm to the nucleus. In conclusion,
TRIM21/Ro52 is a cytoplasmic E3 ligase that is overexpressed in PBMCs from patients with SS
and SLE. TRIM21/Ro52 is induced by IFNα and herpes simplex virus, and inhibits cell
proliferation.
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INTRODUCTION
The main subject of this thesis is the E3 ligase Ro52, and in particular its role in
immunity. Ro52 was first described as an autoantigen in systemic autoimmune
rheumatic diseases, although, lately its role as an ubiquitin ligase has gained
increased attention. With this in mind, this introduction begins with a description
of the ubiquitin system and how the post-translational modification with ubiquitin
is important for the degradation, activation, and sorting of intracellular proteins.
This is followed by an outline of the immune system, autoimmunity and
autoimmune disease, and the role of the ubiquitin system in the regulation of
immune responses. Finally, the main protagonist of this thesis, Ro52, will be
presented in detail and the eventual role of Ro52 in immunity and autoimmune
disease will be discussed.
The ubiquitin system
The intracellular concentration, localization, and activity of proteins must be
carefully controlled in order for cells to function normally. This control is achieved
by regulating several biological processes, e.g. the translation of messenger
ribonucleic acid (mRNA), protein transport, protein modification, and protein
turnover. One important regulatory tool in eukaryotic cells is the post-translational
covalent modification of proteins with ubiquitin (Goldstein et al., 1975), a
polypeptide of 76 amino acid (aa) residues (Schlesinger et al., 1975, Schlesinger and
Goldstein, 1975, Wilkinson and Audhya, 1981). The post-translational modification
with ubiquitin, and the handling of ubiquitinated proteins, is carried out by the
ubiquitin system, reviewed in (Weissman, 2001). This system is highly conserved
among eukaryotes (Sharp and Li, 1987, Tanaka et al., 1992) and can be divided into
two interconnected modules: one, modifying proteins with ubiquitin; and another,
recognizing ubiquitinated proteins and connecting them to effector molecules
through ubiquitin binding adaptor proteins.
Ubiquitin was discovered in 1975 by Goldstein and coworkers (Goldstein et al.,
1975) when searching for novel thymic hormones. They purified ubiquitin from
bovine thymus and described it as a differentiation factor for thymocytes and pre-B
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cells. However, this described role of ubiquitin in lymphocyte differentiation has
failed to be replicated. Instead, the breakthrough in the ubiquitin field came in 1978
when Ciechanover et al. (Ciehanover et al., 1978) demonstrated that ubiquitin was
involved in intracellular non-lysosomal proteolysis. Later publications by the same
investigators (Hershko et al., 1979, Ciechanover et al., 1980, Hershko et al., 1980,
Hershko et al., 1981, Ciechanover et al., 1981) proved that the observed proteolysis
was dependent on adenosine triphosphate (ATP) and MgCl2, and required at least
three novel protein factors called E1, E2 and E3 (Hershko et al., 1983). This work
was later rewarded with the Nobel Prize in Chemistry in 2004.
Ubiquitin and ubiquitin like proteins. The human and mouse genomes have
numerous ubiquitin genes. Although most of them are pseudogenes, four
functional ubiquitin genes have been identified: UbB, UbC, and two UbA genes
(Table 1).
Table 1. Ubiquitin genes
Gene Locus    Genbank ID Reference
Uba52 (M. musculus) Chr8, 35.0 cM 22186 (Sun and Wuthrich, 1999)
UBA52  (H. sapiens) 19p13.1-p12 7311      (Webb et al., 1994)
Rps27A (M. musculus) Chr11, 11 A3.3 78294 (Gerhard et al., 2004)
RPS27A (H. sapiens) 2p16 6233 (Kenmochi et al., 1998)
Ubc (M. musculus) Chr5, 64 cM 22190 (Klingenspor et al., 1997)
UBC  (H. sapiens) 12q24.3 7316 (Board et al., 1992)
Ubb  (M. musculus) Chr11, 35.0 cM 22187 (Klingenspor et al., 1997)
UBB  (H.  sapiens) 17p12-p11.2 7314 (Webb et al., 1990)
Ubiquitin is not expressed as a free monomer, but as an inactive precursor; either
as a polymer (polyubiquitin) or as fusions to ribosomal subunits (Ozkaynak et al.,
1984, Wiborg et al., 1985, Lund et al., 1985, Ozkaynak et al., 1987, Finley et al.,
1989, Baker and Board, 1991). In man and mouse, the UbA genes (UbA52 and
UbA80/Rps27a) encode one ubiquitin molecule fused to the N-terminus of a
ribosomal subunit. After transcription and translation, an active ubiquitin molecule
with two C-terminal glycine residues is released from the ribosomal subunit fusion
partner through endopeptidase cleavage (Agell et al., 1991). The UbA52 gene
encodes ubiquitin fused to the L40 ribosomal subunit (Stoffler et al., 1974), while
UbA80/Rps27a encodes ubiquitin fused to the S27a ribosomal subunit (Collatz et
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al., 1976). In contrast to the UbA genes, UbB and UbC are polyubiquitin genes
encoding head-to-tail tandem repeats of ubiquitin. After translation, active
ubiquitin moieties are released by endopeptidase cleavage.  To ensure that the
ubiquitin precursors are inactive, the last ubiquitin repeat in polyubiquitin genes
encodes an incomplete ubiquitin moiety lacking the C-terminal diglycine motif that
is necessary for activity.
Table 2. Ubiquitin like proteins
Ubl Function Reference
ISG15 Antiviral response; cytokine (Farrell et al., 1979, Reich et al., 1987, Haas et al., 1987)
Nedd8 Transciption;  proteolysis (Kumar et al., 1992)
SUMO-1 Localization; transcription (Shen et al., 1996, Howe et al., 1998)
FAT10 Apoptosis; proteolysis (Fan et al., 1995, Bates et al., 1997)
Since the discovery of ubiquitin, several ubiquitin like proteins (Ubls) have been
described (Table 2). Ubls work in an analogous fashion to ubiquitin, although their
roles in the physiology of the cell differ (Yeh et al., 2000, Kirkin and Dikic, 2007).
Examples of Ubls are small ubiquitin-related modifier (SUMO), neural precursor
cell expressed, developmentally down-regulated 8 (Nedd8), HLA-F adjacent
transcript 10 (FAT10) and interferon stimulated gene 15 (ISG15).
The primary structures of ubiquitin and Ubls are not very similar; nevertheless,
the adopted folds of ubiquitin and Ubls are almost identical (Bayer et al., 1998)
(Fig 1). Ubiquitin has a compact folded structure (Vijay-Kumar et al., 1985, Vijay-
Kumar et al., 1987b, Vijay-Kumar et al., 1987a) and an extraordinary resilience to
extreme temperatures, pH and salt concentrations (Lenkinski et al., 1977).
Figure 1. Ubiquitin and SUMO-1. Ubiquitin (left) and SUMO-1 (right) have a
relatively low sequence similarity; even so, the two proteins adopt a similar fold.
-12-
Post-translational modification with ubiquitin. In contrast to other post-
translational modifications, such as phosphorylation, every single modification with
ubiquitin is dependent on several types of enzymes. Before being covalently
attached to a target protein, ubiquitin first has to be bound and activated by a
ubiquitin activating enzyme (E1) (Ciechanover et al., 1981, Handley et al., 1991,
Disteche et al., 1992). This occurs through an ATP dependent mechanism were the
C-terminal glycine residue (G76) of ubiquitin forms a thioester bond with a
catalytic cysteine residue in the active site of a ubiquitin-activating enzyme (E1)
(Hatfield and Vierstra, 1992). The ubiquitin molecule is then transferred from the
active site on E1 to a cysteine residue on a ubiquitin-conjugating enzyme (E2)
(Jentsch et al., 1987, Goebl et al., 1988, Scheffner et al., 1994). The final step
involves a ubiquitin ligase (E3) (Hershko et al., 1986, Bartel et al., 1990) that
mediates the transfer of ubiquitin from an E2 to an ε-amino group in a lysine
residue of a target protein (Chau et al., 1989). Alternatively, ubiquitin can be
attached to the N-termini of proteins (Bachmair et al., 1986, Breitschopf et al.,
1998). Due to the simultaneous binding of E2 and E3 to a substrate, the
combination of E2 and E3 enzymes determines the specificity of the ubiquitination
process (Zheng et al., 2000).
1 2
3
45
Figure 2. Post-translational modification with ubiquitin.  (1) The C-terminal
glycine (G76) of a ubiquitin molecule is activated and bound by the E1 enzyme in
an ATP dependent manner. (2) The ubiquitin molecule is transferred to an E2
enzyme and attached to a protein substrate with the help of an E3 ligase (3-4).
Several ubiquitin molecules can be sequentially attached to form a polyubiquitin
chain by repeating step 4 (5).
-13-
RING E3 ligases. The most studied types of E3 ligases are those dependent on
the really interesting new gene (RING) domain (Freemont et al., 1991, Lovering et
al., 1993) or the homologous to E6AP carboxyl terminus (HECT) domain
(Huibregtse et al., 1995). While RING E3 ligases function as scaffold proteins
bringing the E2 and target protein together, HECT E3 ligases act as bona fide
enzymes by binding ubiquitin covalently before transferring it to the target protein.
                   
When first identified through sequence database mining (Freemont et al., 1991),
the RING domain, due to its high similarity with the classic zinc finger motif (Berg,
1990), was believed to be a DNA binding domain. Later, however, the RING
domain was shown to mediate protein-protein interactions, especially the binding
of E3 ligases to E2s (Reiss et al., 1989, Zheng et al., 2000). When the first draft of
the humane genome was published, the RING domain was reported to be the 15th
most common domain in the human genome (Lander et al., 2001). RING domains
are 30-110 aa residues large and fold around two Zn2+ ions in a cross-bracelet like
structure (Fig 3A); this folding is dependent on eight conserved cysteine and
histidine residues (Fig 3B) that coordinate the Zn2+ ions. The first atom level
structure of a RING domain was published in 1994 (Barlow et al., 1994).
A
B
Figure 3. The RING fold and the RING consensus sequence. (A) The
RING domain folds around two Zn2+ ions in a cross-bracelet like structure. (B)
The consensus sequence of RING domains; note that the first two, and last two,
cysteine residues are always separated by two amino acid residues. The variation
in size of the two RING loops is large, from 9 to 39 aa residues and 4 to 48 aa
residues respectively.
Zn2+
Zn2+
(4-48 aa)
(9-39 aa)C-C
C-C/H-H-C
C-C
-C-X2-C-X9-39-C-X1-3-H-X2-3-C/H-X2-C-X4-48-C-X2-C-
-14-
Ubiquitination is reversible. Analogous to phosphorylation, ubiquitination is a
reversible process. This deubiquitination is mediated by a large group of
deubiquitinating enzymes (DUBs) (Agell et al., 1991, Amerik and Hochstrasser,
2004), that cleave ubiquitin after the last glycine residue (G76) thereby releasing
intact ubiquitin molecules from ubiquitin chains or ubiquitin conjugates.
DUBs are important in the production of active ubiquitin monomers through
the processing of inactive ubiquitin precursors. In addition, DUBs edit ubiquitin
conjugates on target proteins (‘proofreading’) and recycles ubiquitin monomers
from ubiquitin-modified proteins that are degraded in the proteasome.
Consequently, DUBs maintain and regulate the intracellular pool of free ubiquitin
(Haas and Bright, 1987).
Ubiquitin topology. Importantly, a protein can be modified by ubiquitin in
several ways. Three types of ubiquitination can be identified (Fig 4):
monoubiquitination, multiubiquitination and polyubiquitination reviewed in (Roos-
Mattjus and Sistonen, 2004). However, it cannot be ruled out that combinations of
these might occur.
Monoubiquitination is the modification of a target protein with one single
ubiquitin moiety, while multiubiquitination is the modification of a target protein
with several single ubiquitin moieties, each on a separate lysine residue. In contrast,
polyubiquitination is the result of adding a chain of ubiquitin moieties. These
polyubiquitin chains are probably built through the sequential attachment of
ubiquitin moieties through their lysine residues (Chen and Pickart, 1990), although
it has been suggested that polyubiquitination also might occur through the addition
of a preformed ubiquitin chain (Li et al., 2007a).
Poly-    Mono-       Multi-
Figure 4. Modification with ubiquitin. A protein can be modified by
polyubiquitin, monoubiquitin and multiubiquitin. K48 polyubiquitin chains of >4
ubiquitin moieties are targeted to the proteasome.
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Polyubiquitin chains can be formed through different lysine residues in ubiquitin
(Kirkpatrick et al., 2005). Since one ubiquitin moiety has seven lysine residues (K6,
K11, K27, K29, K33, K48 and K63) at least seven different types of polyubiquitin
chains are possible; and even more can be expected since polyubiquitin chains can
divide and form branches (Peng et al., 2003, Kim et al., 2007). E.g., the sequential
attachment of ubiquitin moieties can occur through lysine 48 (K48) or lysine 63
(K63). Proteins modified with K48 chains are degraded in the 26S proteasome
(Hershko and Heller, 1985, Chau et al., 1989), while K63 chains (Spence et al.,
1995) may protect proteins from proteasome mediated degradation and is
necessary for DNA repair. The topology of K48 and K63 polyubiquitin chains are
distinct: whereas K48 chains have a closed formation driven by hydrophobic
interactions (Cook et al., 1992, Cook et al., 1994, Beal et al., 1998, Phillips et al.,
2001, Varadan et al., 2002) K63 chains adopt a more extended conformation
(Varadan et al., 2004). The conformation of K63 chains hypothetically allows for
an easier access for binding of ubiquitin binding domain (UBD) containing
proteins, while the more compact K48 conformation might be harder to access for
UBDs.
Although ubiquitin topology is a fascinating subject, one word of caution is in
order. All the studies on ubiquitin topology have been made in cell free
reconstituted in vitro systems. It is unclear how these results translate into the
situation in vivo. The development of new experimental tools is required to study
the importance of different ubiquitin modifications in vivo. E.g., antibodies specific
for different polyubiquitin topologies and refinement of existing techniques such as
mass spectrometry (MS) (Kirkpatrick et al., 2005), fluorescence resonance energy
transfer (FRET) or similar techniques (Boisclair et al., 2000, Hong et al., 2003,
Perroy et al., 2004, Hoeller et al., 2006, Fang and Kerppola, 2004),
The different fates of ubiquitin modified proteins. The classical view, that
ubiquitination mainly is important for protein degradation in the non-lysosomal
compartment, is still dominating ubiquitin research. However, it is now appreciated
that ubiquitination is a process that is involved in many facets of cell biology. It
was early shown that plasma membrane proteins could be modified by ubiquitin
(Yarden et al., 1986, Leung et al., 1987) especially after binding to an extracellular
ligand (Mori et al., 1993). That the internalization and degradation of plasma
membrane proteins is mediated by ubiquitination was first discovered in yeast
(Kolling and Hollenberg, 1994, Hicke and Riezman, 1996) and later in mammalian
cells (Strous et al., 1996). In addition, ubiquitination is also necessary for the
activation of several transcription factors either in a proteasome dependent manner
(Palombella et al., 1994) or independently of the proteasome (Kaiser et al., 2000).
-16-
Transcriptional activity is also modified by the ubiquitination of histones (Levinger
and Varshavsky, 1982) as reviewed in (Muratani and Tansey, 2003).
Protein degradation in the proteasome. The 26S proteasome (DeMartino and
Goldberg, 1979, Rose et al., 1979, Wilk and Orlowski, 1980, Orlowski and Wilk,
1981) is a 2.4 MDa large dynamic protein complex dedicated to degrade proteins
modified with K48 polyubiquitin chains, containing at least four ubiquitin moieties
(Thrower et al., 2000), into oligopeptides. It consists of two multisubunit
complexes: one 20S proteolytic core complex and one 19S regulatory complex
(Arrigo et al., 1988) (Fig 5A).
The 20S core proteasome is barrel shaped and built out of four stacked
heptameric rings (Tanaka et al., 1988b, Tanaka et al., 1988a, Unno et al., 2002) (Fig
5B). The two outer rings are composed of seven α subunits (α1-α7) while the two
middle rings our composed of seven β subunits (β1-β7) resulting in a α7β7β7α7
arrangement. The proteolytic chamber is accessible through the 13Å wide openings
at the ends of the cylinder. Entry into the core proteasome is regulated by the α-
subunits in the outer rings, while the proteolytic activity of the proteasome is
mediated by the β1, β2 and β5 subunits on the two middle rings (Hilt et al., 1993,
Zwickl et al., 1994, Lowe et al., 1995, Fenteany et al., 1995).
A B19S
19S
20S
Cap
Base
Protein
Peptides
20S
Figure 5. The proteasome. (A) A longitudinal section of the 26S proteasome
showing the barrel shaped core proteolytic 20S proteasome, and two regulatory 19S
proteasomes. (B) The 20S proteasome is composed of four rings each consisting of
seven subunits; the proteolytic activity is confined to subunits of the two middle
rings.
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In contrast to the 20S proteasome, the 19S proteasome does not have proteolytic
activity, but rather regulates the entry of ubiquitinated protein substrates into the
20S proteasome. The 19S proteasome ‘base’ is composed of six subunits (Rpt1-
Rpt6) with ATPase activity arranged in a ring like structure and placed axially to the
20S proteasome (Dubiel et al., 1992, Lucero et al., 1995, Glickman et al., 1998,
Baumeister et al., 1998). Protruding from this ATPase base is a ‘cap’ (Fig 5A); this
19S cap structure recognizes polyubiquitin chains on proteins to be degraded. In
addition, the 19S proteasome unfolds protein substrates, removes ubiquitin chains
and funnels proteins into the proteolytic core of the 20S proteasome, reviewed in
(Pickart, 1997, Wolf and Hilt, 2004).
The composition of the 20S proteasome is modified in response to e.g. viral
infections. Infections with viruses, or intracellular bacteria, induce the production
of interferon γ (IFNγ) which in turn leads to the expression of new proteasomal
subunits creating a modified proteasome, the immunoproteasome, which produces
peptides with enhanced binding to the major histocompatibility complex I (MHC
I) cleft. (Yang et al., 1992, Gaczynska et al., 1993).
Proteasome-independent roles of ubiquitination. Ubiquitination of proteins
does not necessarily lead to their degradation in the proteasome. The modification
of a target protein with ubiquitin may e.g. lead to the sorting into the lysosome
(Strous et al., 1996) or modification of transcriptional activity (Ostendorff et al.,
2002).
The termination of receptor signaling in response to excessive amounts of
extracellular ligands, i.e. receptor ‘downregulation’, is an important negative feed
back mechanism, for reviews see (Fiorini et al., 2001, Dikic and Giordano, 2003).
One major such negative feedback mechanism is the endocytosis of
transmembrane proteins, after which they are either degraded in the lysosomes, or
recycled back to the plasma membrane. The decision between recycling or
degradation is regulated by the ubiquitin system (Hicke, 1997, Hicke, 2001), for
review see (Mukhopadhyay and Riezman, 2007). It is commonly observed, that
mammalian cells surface receptors, such as receptor tyrosine kinases (RTKs) and
G-protein coupled receptors (GPCRs), are internalized into the endosomal
compartment. E.g., the RTK endothelial growth factor receptor (EGFR) is
ubiquitinated and internalized after exposure to high concentration of ligand (Stang
et al., 2000, de Melker et al., 2001, Sigismund et al., 2005). In the article by Stang et
al., polyubiquitination of the EGFR was reported, indicating a possible role for the
proteasome. However, due to technical difficulties of differentiating between
multiubiquitination and polyubiquitination (both modifications might be detected
as smears after immunoblotting) the issue of polyubiquitination versus
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monoubiquitination is not altogether clear. Haglund et al. (Haglund et al., 2003)
used molecular biology techniques and antibodies with different affinities for
mono- and polyubiquitin, to show that the internalization of EGFR is indeed
dependent on multiubiquitination and not polyubiquitination.
Recycling of internalized cargos to the cell surface occurs by default (Mayor et
al., 1993); in contrast, cargos to be sorted into the lysosomes need to be labeled
with ubiquitin through the coordinated action of E1, E2, and E3 proteins. The
exact mechanism by which ubiquitin mediates the sorting of internalized cargos to
the lysosomes is still being investigated. In general, the recognition of ubiquitinated
cargos is mediated by UBD containing proteins, e.g. Eps15, Hrs, and Tsg10, that
function as sorting receptors (Benmerah et al., 1995, Babst et al., 2000, Polo et al.,
2002, Lu et al., 2003). Internalized cargos to be degraded in the lysosome are
transported through the early endosomal compartment to the late endosomal
compartment. Invagination of the limiting membrane of late endosomes leads to
the inward budding of intralumenal vesicles (ILVs); forming ILV-containing late
endosomes called multivesicular bodies (MVBs). After fusion of MVBs with
lysosomes, ILVs and their content (including membrane proteins) are degraded by
lysosomal enzymes (Piper and Katzmann, 2007).
In all, ubiquitinated proteins from the cell surface or the late Golgi complex are
directed to MVBs, preferentially incorporated into ILVs and finally directed to the
lysosomes. Non-ubiquitinated proteins are recycled from the endosomes or MVBs.
In contrast to membrane proteins or proteins in the late Golgi network, proteins in
the early secretory compartments are degraded by the proteasome through
endoplasmic reticulum-associated degradation (ERAD) (Meusser et al., 2005,
Kostova et al., 2007).
Ubiquitin binding domains. The recognition of ubiquitin-modified proteins is
achieved through ubiquitin binding proteins. Recognition of ubiquitinated protein
is mediated through UBD domains reviewed in (Hicke et al., 2005), and the broad
recognition specificity is achieved through the use of a multitude of different UBD
domains (Table 3). UBDs have a low to moderate affinity for ubiquitin and this
raises the question whether they bind preferentially to monoubiquitin or
polyubiquitin (Hicke et al., 2005). Intuitively, ubiquitin receptors that bind
polyubiquitinated proteins and deliver them to the proteasome have a high affinity
for polyubiquitin.
The hierarchical organization of the ubiquitin system. Every post-
translational modification of a protein presents a problem of specificity. How can a
specific protein be ubiquitinated while leaving bystander proteins unmodified?
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Moreover, how can the ubiquitin system specifically recognize a certain
ubiquitinated protein? The ubiquitin system solves the specificity problem of
ubiquitination by using multiple proteins to modify target proteins, and multiple
proteins to recognize ubiquitinated proteins. Thus, a large number of E3 ligases
(>400) are needed in order to achieve the high specificity; in contrast, fewer E2s
(~50) and only one E1 are required.
Table 3. Ubiquitin binding domains
Ubiquitin binding domain Reference
UBA (ubiquitin-associated domain) (Hofmann and Bucher, 1996)
UEV (ubiquitin-conjugating E2 enzyme variant) (Sancho et al., 1998)
UIM (ubiquitin-interacting motif) (Hofmann and Falquet, 2001)
NZF (Npl4 zinc finger) (Meyer et al., 2002)
PAZ (polyubiquitin-associated zinc finger) (Hook et al., 2002)
CUE (coupling of ubiquitin conjugation to ERAD) (Donaldson et al., 2003, Shih et al., 2003)
VHS (Vps27, HRS, STAM) (Mizuno et al., 2003)
GAT (Gga and Tom1) (Shiba et al., 2004)
GLUE (GRAM-like ubiquitin-binding in Eap45) (Slagsvold et al., 2005)
The deletion of E1 is lethal in yeast and metazoans (McGrath et al., 1991,
Zacksenhaus and Sheinin, 1990), whereas the deletion of E2s or E3s may be lethal
but often lead to varying less severe phenotypes (Table 4). Interestingly, mice
lacking some E2s and E3s manifest phenotypes with a large immunologic
component. E.g., gene targeted mice deficient in the E2 enzyme Ubc13 (Ubc13-/-)
die during early embryogenesis, but survive if Ubc13 is genetically ablated only in B
lymphocytes (Yamamoto et al., 2006). Interestingly, these Ubc13-/- B lymphocytes
are defective in several signaling pathways e.g. toll-like receptor (TLR) signaling.
Furthermore, a Drosophila mutant (bendless) with a missense mutation in the active
site region of the Ubc13-/- ortholog has a defective development of the central
nervous system (Muralidhar and Thomas, 1993). Mice lacking either one of the
RING E3 ligases Casitas B-lineage lymphoma b or c (Cbl-b-/- or Cbl-c-/-) have
dysregulated T cell signaling, and mice deficient in the E3 ligase tripartite-motif
protein 25 (TRIM25-/-) have an attenuated antiviral response due to defective
retinoic-acid inducible gene 1 (RIG-1) signaling (Murphy et al., 1998, Bachmaier et
al., 2000, Gack et al., 2007a).
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Table 4. Phenotypes of mice with mutant E2s and E3s
Mutant Phenotype Reference
c-Cbl-/- Lymphoid hyperplasia (Murphy et al., 1998)
Itchy Autoimmune disease (Perry et al., 1998)
TRIM25-/-     Developmental., antiviral response (Orimo et al., 1999, Gack et al., 2007a)
Cbl-b-/- Hyperproliferating lymphocytes (Bachmaier et al., 2000)
TRIM28-/-      Embryonic lethal (Cammas et al., 2000)
Ubc13-/- Embryonic lethal; impaired B cell response. (Yamamoto et al., 2006)
E3 ligases and immune cell responsiveness. E3 ligases are involved in all
fundamental biological processes, e.g. the cell cycle, apoptosis, neurogenesis and
the immune response. Interestingly, many E3 ligases seem to regulate the activation
threshold of immune cells by ubiquitinating different substrates, ranging from cell
surface receptors to transcription factors. E.g., the E3 ligase Itch mediates the
ubiquitination and degradation of the activator protein 1 (AP-1) subunit c-Jun
(Gao et al., 2004), thus down regulating the expression of many AP-1 dependent
cytokine genes. The Cbl E3 ligase family control many signaling events through the
ubiquitination of cell surface receptors and signaling molecules, and SMAD
ubiquitination regulatory factor (Smurf) 1 and 2 regulate signaling induced by
transforming growth factor β (TGF-β) (Zhu et al., 1999, Kavsak et al., 2000, Lin et
al., 2000, Zhang et al., 2001).
★
Immunity and the ubiquitin system
The post-translational modification of proteins with ubiquitin and Ubls plays an
important role in most biological processes in eukaryotes. As a result, organs and
multicellular systems of metazoans are dependent on the ubiquitin system to
function normally. One good example is the immune system in which intracellular
signaling pathways are regulated through the ubiquitination of several signaling
proteins. E.g., the activation of the nuclear factor of kappa light chain gene
enhancer in B-cells (NFκB) transcription factors (Sen and Baltimore, 1986b, Sen
and Baltimore, 1986a) require the activation of the inhibitor of NFκB kinase (IKK)
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and the degradation of the inhibitor of NFκB (IκB). The activation of IKK, and
the degradation of IκB, occurs through ubiquitination: IKK activation through
K63 polyubiquitination (Deng et al., 2000), and IκB degradation through K48
polyubiquitination (Chen et al., 1995, Scherer et al., 1995, Alkalay et al., 1995,
DiDonato et al., 1995, DiDonato et al., 1996). The activation of some NFκB
subunits is necessary for an immune response, as evident in immunodeficient p50-/-
mice (Sha et al., 1995), while other NFκB subunits are important in modulating
immune responses as seen in RelB-/- mice (Weih et al., 1995).
Immunity. The immune system is an intricate system of cells and molecules that
gives the host the benefit of immunity; a state in were the host is protected, albeit
incompletely, against infections with e.g. pathogenic microorganisms and
opportunistic parasites.
The immune system is often classified into two branches: the innate, and the
acquired immune system. The innate immune system is dependent on germ line
encoded pathogen recognition receptors, and is therefore present from birth. In
contrast, the acquired immune system requires the creation and selection of new,
unique, antigen receptors through the process of somatic recombination (Hozumi
and Tonegawa, 1976). Consequently, the acquired immune system needs time to
develop and mature before being functional, reviewed in (Landreth, 2002).
Immune cells. Immune cells are produced exclusively in the bone marrow and are
found through out the body of both rodents and humans; furthermore, immune
cells have the characteristic property of being highly able to migrate. E.g., dendritic
cells are stationary at the outer and inner linings of the body until they are
activated. They then migrate to secondary lymphatic organs where they present
antigen to naïve T cells. In contrast, monocytes and neutrophils circulate in the
blood until they eventually migrate into the tissues. By being able to migrate the
immune cells can be assembled, and coordinated, to thwart infections.
It was early predicted that each T and B lymphocyte clone would express a
single type of antigen receptor with a unique specificity (Burnet, 1959). Although
this prediction later was shown to be valid, important exceptions have been
discovered (Padovan et al., 1993, Zal et al., 1996).
Both T and B cells originate from the bone marrow but differ in their site of
maturation. While the maturation process of B cells occurs in the bone marrow,
the T cell maturation take place in the thymus, reviewed in (Hardy and Hayakawa,
2001, Ciofani and Zuniga-Pflucker, 2007, Ye and Graf, 2007). Furthermore, B and
T cells differ in how their antigen receptors recognize antigen. The T cell antigen
receptor (TCR) only recognizes peptide antigens presented on MHC I or MHC II
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molecules (Rosenthal and Shevach, 1973, Zinkernagel and Doherty, 1974), while
the B cell antigen receptor (BCR) recognize surfaces of several classes of molecules
directly, e.g. proteins, carbohydrates and lipids. Peptides for MHC I are produced
by the proteasome (Michalek et al., 1993) while peptides for MHC II are produced
in the lysosomes after endocytosis (Waldron et al., 1974, Buus and Werdelin, 1986).
Another type of lymphocyte is the natural killer (NK) cells (Kiessling et al.,
1975b, Kiessling et al., 1975a), which are involved in the recognition and killing of
virus infected cells and tumor cells. This recognition is not dependent on antigen
receptors, but rather on a large number of activating (Anegon et al., 1988,
Cassatella et al., 1989, Frey et al., 1991) and inhibitory receptors (Karlhofer et al.,
1992, Moretta et al., 1993). While interacting with target cells, NK cells receive
signals through activating and inhibitory receptors, and depending on the type of
signal that dominates, NK cells might destroy the target cell. Target cells that
cannot deliver inhibitory signals, e.g. through MHC I (Karre et al., 1986), are likely
to be killed by NK cells. As suggested by the ‘missing-self’ hypothesis these
inhibitory signals are delivered exclusively by ‘self cells’, i.e. syngeneic, healthy,
untransformed and non-infected cells (Kärre, 1981).
Positive and negative selection of T and B cells. During T and B cell
ontogeny, their antigen receptor genes are assembled through somatic
recombination. This is followed by an imperfect selection process were cells
expressing antigen receptors with strong affinity for self-molecules are deleted.
Negative selection deletes T cells with TCRs of high affinity for MHC/self-
peptides in the thymus (Kappler et al., 1987, McDuffie et al., 1988). Similarly, B
cells with BCRs of high affinity for self-antigens in the bone marrow are deleted
(Goodnow et al., 1989). Positive selection ensures the survival only of T cells with
TCRs of low affinity for MHC/self-peptide (Kisielow et al., 1988, von Boehmer et
al., 1988, von Boehmer et al., 1989), and of BCRs with low affinity for self-antigens
(Lam et al., 1997, Hayakawa et al., 1999). T cells whose TCR receives a positive
selection signal via MHC I develop into cluster of differentiation 8 (CD8+) T cells,
while those who receive a positive selection signal via MHC II develop into CD4+
T cells (Teh et al., 1988). Consequently, CD4+ T cells are activated by antigen
presenting cells (APCs) presenting antigen on MHCII, while CD8+ cells recognize
peptides presented on MHC I.
Positive and negative selection of T and B cells ensures that cells with high
affinity for self-antigens die, while cells with low/moderate affinity for self-antigens
survive.  In this way, only useful cells, with a potential for recognizing foreign
antigen, survive while useless and dangerous cells are deleted.
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Activation of lymphocytes. The activation of T cells is mediated through the
presentation of antigenic peptides by MHC molecules on APCs (Rosenthal and
Shevach, 1973, Zinkernagel and Doherty, 1974). Mature DCs can activate naïve T
cells, while macrophages and B cells only can reactivate previously activated T cells
(Inaba and Steinman, 1984, Inaba and Steinman, 1985, Ronchese and Hausmann,
1993). Activated T cells start to proliferate and may in turn activate B cells and
macrophages.  Depending on the cytokine environment in which naïve T cells
differentiate into their effector phenotype, they can develop into at least four
distinct lineages: Th1 and Th2 (Tada et al., 1978, Mosmann et al., 1986), Th17
(Harrington et al., 2005, Park et al., 2005) or regulatory T cells (Tregs) (Sakaguchi et
al., 1995).
B cells activated by T cells in secondary lymphoid organs start to proliferate,
undergo affinity maturation (Eisen and Siskind, 1964), class switching (Wang et al.,
1970) and finally differentiate into memory B cells or antibody producing plasma
cells. Affinity maturation requires that dividing activated B cells undergo somatic
hyper mutation (Kim et al., 1981). B cells that have, through mutation, produced
BCRs with higher affinities for the inducing antigen will be expanded on the
expense of the B cells that produced BCRs with lower affinities.
Tolerance. The cells of the immune system are tuned to be activated by infectious
or noxious antigens, but not by self-antigens; this state is called tolerance. In a classic
article, Owen gave the first description of immunological tolerance (Owen, 1945)
where he described how bovine dizygotic twins do not reject each other's blood
cells despite a common circulation (placental anastomosis). Later, by using skin
grafting experiments on mice, it was shown that tolerance develops actively during
early fetal life (Billingham et al., 1953), a study that was rewarded with the Nobel
Prize in Physiology or Medicine 1960. This work demonstrated that all antigens
‘seen’ by the immune system during early life are perceived as self.
Tolerance is achieved through central tolerance, where most autoimmune T and
B cells are deleted or inactivated through negative selection, and through peripheral
tolerance where T and B cells that recognize self-antigens are kept inactive through
anergy or ignorance (Nossal and Pike, 1980, Nossal, 1987, Kappler et al., 1987,
Goodnow et al., 1989). The molecular pathways of tolerance are still unclear, but
ubiquitin E3 ligases have been implicated: e.g., the gene related to anergy in
lymphocytes (GRAIL) (Anandasabapathy et al., 2003, Seroogy et al., 2004) and
Cbl-b (Bachmaier et al., 2000). In addition, Tregs modulate CD4+ and CD8+ T cell
responses and are critical for self-tolerance (Sakaguchi et al., 1995, Hori et al., 2003,
Fontenot et al., 2003, Fontenot et al., 2005). Despite all this, tolerance is never
complete and therefore autoimmune cells are always present. Thus, under certain
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conditions autoimmune cells can be activated and initiate an escalating
autoimmune response leading to autoimmune disease.
★
Autoimmunity and autoimmune disease
Several chronic inflammatory diseases, such as rheumatoid arthritis (RA) and
multiple sclerosis, are classified as autoimmune diseases; this based on clinical
findings, e.g. inflammatory cell infiltrates in the affected organs and high levels of
autoantibodies in patient sera. However, it is unknown to which extent these
diseases are bona fide autoimmune diseases. A true autoimmune disease can be
defined by criteria analogous to the famous Henle-Koch postulates (Koch, 1884,
Inglis, 2007). These criteria must be fulfilled before affirming that a disease is directly
caused by autoantibodies or autoimmune cells. (1) All patients with the disease must
have autoantibodies (autoreactive lymphocytes) directed against at least one
autoantigen in the affected tissue, and these autoantibodies (autoreactive
lymphocytes) must be present in the affected tissue. (2) It must be possible to
purify these autoantibodies (autoreactive lymphocytes) from patients. (3) These
purified autoantibodies (autoreactive cells) must induce the same disease if
transferred to a healthy subject. (4) Removal of the same autoantibodies
(autoreactive cells) from patients must eliminate (or at least ameliorate) the disease
progression, and finally (5) immunization with the corresponding autoantigen must
induce a similar disease.
In animal models, the minimal genetic and environmental variation makes the
fulfillment of these criteria possible (Kouskoff et al., 1996, Matsumoto et al., 1999,
Korganow et al., 1999, Matsumoto et al., 2002, Schubert et al., 2004). In contrast,
the criteria are difficult to fulfill in human subjects. This is due to the large variation
in genetic background and environmental exposure between individuals, resulting
in a high variation in the susceptibility to autoimmune disease. Consequently, the
transfer of autoimmune disease from a susceptible individual to a resistant
individual is unlikely.  However, circumstantial evidence corroborates the idea that
a certain disease is indeed autoimmune in origin. E.g., allogeneic bone marrow
transplantations have been reported to transfer disease in a few cases (Wyatt et al.,
1990, Haslam et al., 1993, Marazuela and Steegman, 2000). Moreover,
immunosuppression is generally beneficial for patients and targeted therapies
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against inflammatory mediators (e.g. tumor necrosis factor) or immune cells (e.g.
CD20+ B cells) do in many cases improve the disease.
From autoimmunity to autoimmune disease. After tissue trauma, or following
an immune response against a non-self antigen, an autoimmune episode might be
observed. These transient autoimmune responses may arise after infection and can
cause further pathogenicity, e.g. rheumatic heart fever or reactive arthritis.
Reportedly, transient autoimmune reactions might be necessary for healing and
recovery after tissue trauma as reviewed in (Kipnis and Schwartz, 2005).
In contrast to transient autoimmune episodes, a chronic autoimmune disease
does not resolve. What causes the chronicity of the autoimmune reaction?
Possibilities range from a defective Treg population unable to modulate an ensuing
autoimmune response, to chronic cryptic infections that lead to persistent
stimulation of the innate immune system, feeding the autoimmune response.
A chronic inflammatory disease with typical autoimmune features is myasthenia
gravis, in which autoimmune plasma cells produce autoantibodies that bind and
block the acetylcholine α-receptor at post-synaptic neuromuscular junctions.
Consequently, the disease is characterized by muscle weakness and muscle fatigue.
Other autoimmune diseases are associated with massive infiltration of autoreactive
T cells into the affected tissue. E.g., in insulin dependent diabetes mellitus (type I
diabetes) the islet of Langerhans are infiltrated by autoimmune T cells  followed by
the destruction of the insulin producing β cells.
Per definition autoimmune cells recognize self-antigens, i.e. autoantigens,
through the BCR on autoimmune B cells or through the presentation of self-
peptides on MHC I and MHC II to the TCRs of autoimmune T cells. Although
necessary, the presence of autoimmune cells is not sufficient to initate an
autoimmune response. A requirement for the induction of an autoimmune
response is that autoimmune T cells are activated by professional APCs presenting
peptides from the corresponding autoantigen. An activated autoimmune
(autoreactive) T cell clone can then in turn activate autoimmune B cells presenting
the peptides from the same autoantigen. Activated autoimmune B cells undergo
class switch, affinity maturation and differentiate into autoimmune plasma cells
producing antibodies against self-antigens, i.e. autoantibodies.
Autoreactive effector T cells can activate other cells that in turn can mediate
direct tissue damage. E.g., Th1 cells secrete IFNγ (Mosmann et al., 1986) that
activate macrophages, who in turn secrete proteases and reactive oxygen species
(Schultz and Kleinschmidt, 1983), similarly Th17 cells secrete IL-17 species that
activates a cell mediated response, reviewed in (Kolls and Linden, 2004). In
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contrast, Th2 cells stimulate a humoral immune response through the release of
e.g. IL-4 and IL-10 (Mosmann et al., 1986).
Autoantigens and autoantibodies. Intracellular proteins are not normally
presented on MHC II in conjunction with costimulatory signals. This since the
digestion of apoptotic material by macrophages is a tolerogenic process (Fadok et
al., 1998), i.e. no induction of costimulatory signals on the macrophages occurs.
Therefore the activation of naïve CD4+ T cells by dendritic cells, or the reactivation
of primed CD4+ T cells, mainly occur after tissue damage or infection. Despite this,
patients with systemic lupus erythematosus (SLE) produce large amounts of
autoantibodies against double stranded deoxyribonucleic acid (dsDNA). Many
other intracellular autoantigens have also been described (Table 5), e.g. Ro/SSA,
La/SSB, phospholipids, and Jo-1. One hypothesis is that due to excessive
apoptosis, or defective clearance of apoptotic cells, exposed intracellular
autoantigens can be bound by autoimmune B cells, engulfed by endocytosis and
then presented to autoimmune T cells via MHC II. The T cells, in turn, provide
costimulation for B cells leading to the production of memory B cells and
autoantibody secreting plasma cells. These events could initiate an autoimmune
response. However, it is not clear how an autoimmune response is perpetuated and
escalates into autoimmune disease. One possibility is that a viral infection induces
excessive cell death and the exposure of intracellular proteins. This, together with
activation of immune cells by the virus, will provide both intracellular proteins and
the induction of costimulation (Rosen et al., 1995). The autoimmune reaction
could then be driven by the continuous release of endogenous danger signals from
the damaged tissue. Recurrent viral infections might feed the ongoing response and
lead to a progressive disease. A multitude of scenarios can explain how self-
antigens can activate T or B cells. The insulting epitope might not have been
present in the thymus or the bone marrow (cryptic epitope) preventing negative
selection against it. Alternatively, neo-epitopes might be formed through post-
translational modification or epitopes in viruses might induce a response against
cross reactive self epitope (molecular mimicry).
Are autoantibodies pathogenic?  There is no direct evidence that
autoantibodies (Table 5) are indeed pathogenic except for in a few autoimmune
diseases, e.g. myasthenia gravis, Grave’s disease, Goodpasture’s syndrome, SLE,
and autoimmune congenital heart block. These diseases can be transferred by
autoantibodies, either naturally i.e. from mother to fetus, or artificially e.g. during
blood transfusions or bone marrow transplantations.
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Table 5.  Autoantigens in autoimmune rheumatic diseases (Routsias et al., 2006)
Disease Autoantigen Frequency
Systemic lupus erythematosus dsDNA 65-75%
Ro/SSA (Ro60 and Ro52) 30-40%
La/SSB (La48)   10-15%
Phospholipid 30-50%
Sjögren's syndrome Ro/SSA 70%
La/SSB 70%
IgG 85%
Idiopathic inflammatory myopathies Jo-1 25-30%
Other chronic autoimmune diseases such as RA, idiopathic inflammatory
myopathies multiple sclerosis and insulin dependent diabetes mellitus are driven
mainly by autoimmune Th1 or/and Th17 cells.
Systemic lupus erythematosus and Sjögren’s syndrome. Rheumatic diseases
belong to a heterogeneous group of diseases that may be either autoimmune or
non-autoimmune. Autoimmune rheumatic diseases such as RA, SLE and Sjögren’s
syndrome (SS), all have two common features: they are more prevalent among
females than males and they are associated with certain human leukocyte antigen
(HLA) haplotypes.
SLE and SS are considered to be overlapping diseases but still they are different
in many ways. Clinically, SLE is a more severe disease and may lead to multiorgan
failure and premature death, while SS most commonly engage exocrine organs.
Both patients with SS or SLE have an increased risk of developing B cell
lymphomas (Talal and Bunim, 1964, Voulgarelis and Moutsopoulos, 2003), though
the diseases also have distinct immunological features. E.g., SLE patients often
have an increased CD27+ population in the circulation, consisting of memory B
cells and plasma cells, in contrast SS patients have a diminished CD27+ population
both in absolute and relative numbers compared both to healthy subjects and SLE
patients.  In addition, patients with SS are also usually not B cell lymphopenic,
which is a very common observation amongst SLE patients (Odendahl et al., 2000,
Hansen et al., 2002, Dorner and Lipsky, 2004, Hansen et al., 2004).
★
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Tripartite-motif proteins and immunity
Members of the TRIM protein family are E3 ligases (Reymond et al., 2001, Meroni
and Diez-Roux, 2005) characterized by an N-terminal TRIM motif, i.e. the co-
occurrence of one RING domain, one or two B-box domains (Borden et al., 1993)
and one coiled-coil region. The difference in the C-terminal domain between
TRIM proteins suggests that the TRIM motif is a highly conserved effector motif,
whilst the non-conserved C-terminal domain mediates binding specificity to
different targets. The potential role of TRIM proteins in innate antiviral responses
has been highlighted (Nisole et al., 2005), emphasizing the importance of E3 ligases
in immunity. Many TRIM proteins have been shown to be restriction factors for
viruses; e.g. TRIM1 (Yap et al., 2004), TRIM5 (Stremlau et al., 2004), TRIM19
(Chelbi-Alix et al., 1998), TRIM22 (Tissot and Mechti, 1995), TRIM25 (Gack et al.,
2007b) and TRIM28 (Wolf and Goff, 2007). Furthermore, the notion of antiviral
TRIMs is strengthened by the observation that many TRIMs are upregulated by
interferons (Tissot and Mechti, 1995, Rhodes et al., 2002, Asaoka et al., 2005, Zou
and Zhang, 2006). That some TRIMs have been reported to be inefficient at
restricting viruses (Li et al., 2007b) could be interpreted as if that not all TRIMs are
involved in antiviral immunity. However, it could be argued that these TRIMs were
only ineffective against the tested viruses; they might have a strong effect against
yet non-tested viruses. Thus, it is not unlikely that the TRIM family is a large group
of antiviral restriction factors and that more TRIMs will be identified as antiviral
proteins
TRIM21/Ro52. The history of the intracellular protein Ro52 (a.k.a. TRIM21,
RNF81) is deeply rooted in the field of rheumatology. That patients with systemic
rheumatic diseases, in particular SLE and SS, have antibodies to an autoantigen
called Ro/SSA has been known since the late 60’s (Clark et al., 1969, Mattioli and
Reichlin, 1974, Alspaugh and Tan, 1975). These anti-Ro/SSA autoantibodies have
been used as a diagnostic tool for decades although the molecular identity of the
Ro/SSA autoantigen was unknown. Ro/SSA was consequently found to consist of
at least two proteins; Wolin et al. first identified Ro60 (Wolin and Steitz, 1984)
subsequently Ben-Chetrit et al. (Ben-Chetrit et al., 1989) and Wang et al. (Wang et
al., 1996) cloned the complementary DNA (cDNA) of Ro60. Ben-Chetrit and
colleagues gave the first description of Ro52 by discovering that a 52 kD protein
(Ro52) was a part of the Ro/SSA autoantigen (Ben-Chetrit et al., 1988). Three
years later the cDNA of human Ro52 was cloned independently by two groups
(Chan et al., 1990, Chan et al., 1991, Itoh et al., 1991); subsequently the human
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Ro52 gene was mapped to chromosome 11 (Frank et al., 1993) and the exon-
intron structure was elucidated (Chan et al., 1995).
The nomenclature surrounding Ro52 is confusing. Ro/SSA can mean either
Ro52 or Ro60, or both; therefore, Ro52 is often described as the 52 kDa
component of Ro/SSA, i.e. Ro/SSA 52 kDa or SSA/Ro 52kD. However, the two
most common symbols are Ro52 and TRIM21 (Reymond et al., 2001). TRIM21 is
the official gene symbol approved by the HUGO Gene Nomenclature Committee,
therefore, the recommendation is to use the symbol TRIM21 to denote both the
protein and the gene.
The TRIM/Ro52 gene is approximately 8 kb in size and consists of eight (mouse)
or seven (human) exons and has a conserved exon-intron structure (Fig 6). The
RING and B-box domains are encoded by exons 3 and the B30.2 domain is
encoded by the last exon (Fig 6 and 7). In the human and mouse genomes there
are two large paralogous TRIM gene clusters. TRIM10, 15, 26, 27, and 31 are
located on chromosome 6 in man, and 17 in mouse. TRIM5, 6, 21, 22, and 34 are
located on chromosome 11 in man, and 7 in mouse.
The B-box domain (Borden et al., 1993) is unique for the TRIM family and is
like the RING domain a Zn2+ binding domain although the B-box consensus
sequence distinguishes it from the RING domain. Two coiled-coil (CC) domains,
CC-1 and CC-2, are predicted by using a coiled-coil prediction algorithm (Lupas et
al., 1991). CC-1 has a lower prediction score, especially in mouse, while CC-2 has a
high prediction score. In addition, CC-2 contains a putative leucine zipper motif
Figure 6.  The gene structure of TRIM21/Ro52. The exon-intron structure of
the TRIM21 gene is similar in mouse and human. The mouse gene is located on
chromosome 7 and the human gene on chromosome 11 (11p15.5).
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making CC-2 a good candidate to be a homo- or hetero interaction domain. A
B30.2 domain (Vernet et al., 1993) is located C-terminal of the TRIM motif. The
B30.2 contain the subdomains splA and RyR (SPRY) and associated with SPRY
(PRY) (Ponting et al., 1997), together referred to as the PRYSPRY domain
(Rhodes et al., 2005). The B30.2 domain of Ro52 has been implicated in binding to
the constant part of the IgG heavy chain (Yang et al., 1999, Yang et al., 2000,
Rhodes and Trowsdale, 2006, James et al., 2007) and to the interferon responsive
factor (IRF) 8 (Kong et al., 2007).
TRIM21/Ro52 is reportedly a ubiquitously expressed protein as determined by
in situ hybridization (Reymond et al., 2001) (www.tigem.it/TRIM); although,
ubiquitous expression at the protein level has not been corroborated by
experimental data. However, no failed attempt to detect Ro52 at the mRNA and
protein level from different tissues has been reported.
Anti-Ro/SSA positive sera affinity purified against Ro52 is commonly used to
detect Ro52. This is an approach suffering from non-specific staining; instead, the
preferred method of detecting Ro52 is by using anti-Ro52 monoclonal antibodies.
A powerful approach to detect Ro52 expressing cells in vivo is by using a genetic
reporter system wherein a reporter protein, e.g. green fluorescent protein (GFP), is
expressed from the endogenous Ro52 promoter. By knowing which cell types
express Ro52, it is possible to gain information regarding the function of Ro52.
Figure 7. The domain structure of the protein TRIM21/Ro52. The RING,
B-box and coiled-coil domains together constitute the TRIM motif. Two predicted
coiled-coil domains and one B30.2 domain are located C-terminal to the TRIM
motif. Coiled-coil 2 contains a putative leucine zipper motif.
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E.g., if Ro52 expression occur only in differentiated cells of a lymphoid cell lineage,
Ro52 is likely to have a role in the differentiation or effector function of these cells.
The function of TRIM21/Ro52. The biological function of Ro52 is not known,
however, experimental data accumulating during the last decade have given
important clues to its roles in e.g. IgG binding, IL-2 and IL-12 production and in
the cell cycle (Yang et al., 1999, Yang et al., 2000, Ishii et al., 2003, Rhodes and
Trowsdale, 2006, Sabile et al., 2006, James et al., 2007, Kong et al., 2007).
That Ro52 is an E3 ligase was first demonstrated by (Wada and Kamitani,
2006a) and later corroborated and expanded by the same and other authors
(Espinosa et al., 2006, Sabile et al., 2006, Wada and Kamitani, 2006b, Wada et al.,
2006, Kong et al., 2007). Although it is clear that Ro52 is an E3 ligase, its substrate
is unknown. By searching for interaction partners of Ro52, several research groups
have found putative substrates; e.g., IgG heavy chain (Yang et al., 2000, Yang et al.,
1999, Takahata et al., 2007), p27 (Sabile et al., 2006) and  IRF-8 (Kong et al., 2007).
The best-characterized interaction partner for human Ro52 is human IgG1 and
IgG4 heavy chain. This interaction, occuring between the B30.2 (PRYSPRY)
domain of Ro52 and the constant part of IgG heavy chain (Yang et al., 1999), was
already noted by Buyon et al. (Buyon et al., 1994). Human Ro52 does not,
however, seem to interact with mouse IgG (Rhodes and Trowsdale, 2006). The
B30.2 domain of TRIM21/Ro52 (and other TRIMs) has a β-sandwich like core
domain with six extended variable loops. Analogous to the immunoglobulin fold in
antibodies, the variable loops seem to have diverged to different specificities while
the core domain is more conserved. The PRY and SPRY subdomains of B30.2
form binding pockets for the CH2 and CH3 domains of IgG heavy chain
respectively, the same domains of IgG that are also bound by protein-A and G.
The affinity of the TRIM21/Ro52 B30.2 domain for the IgG heavy chain has been
estimated to KD=3.7x10
-9 M (James et al., 2007), a very high affinity when
comparing to the KD=8x10
-7 M for the protein-G:IgG interaction (Sjobring et al.,
1991), and the TRIM21/Ro52:B30.2 stoichometry to 2:1.. The physiological
consequence of this TRIM21/Ro52-IgG interaction is presently unknown, but it
cannot be excluded that it plays a role in the pathogenesis. TRIM21/Ro52 released,
after e.g. apoptosis, might hinder the clearing of immune complexes by binding the
IgG Fc part; blocking the binding of immune complexes by FcγR expressing cells.
Although the B30.2 domain does not bind the same part of IgG as FcγR, the
binding of IgG by FcγR might still be outcompeted. One possibility is also that
TRIM21/Ro52 is involved in controlling IgG levels, or IgG trafficking, by
ubiquitination.
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In addition to IgG, TRIM21/Ro52 also binds and ubiquitinates IRF-8 in a
B30.2 dependent manner (Kong et al., 2007). IRF-8 is ubiquitinated and stabilized
by TRIM21/Ro52, thereby increasing the transcription of IRF-8 induced genes,
e.g. the IL-12 subunit p40. Furhermore, ectopic overexpression of TRIM21/Ro52
increased the production of IL-12 in macrophages. This enhancement of IRF-8
transcriptional activity through ubiquitination is an example of how ubiquitin acts
independently of the proteasome.
In all, data is accumulating demonstrating that TRIM21/Ro52 is an E3 ligase
ubiquitinating multiple proteins involved in immunity. However, the cell biological
function of TRIM21/Ro52 is still not well studied; and the functional role of
TRIM21/Ro52 in regulating immune responses in vivo is completely unknown.
★
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AIMS
The protein TRIM21/Ro52 was first described as an autoantigen in rheumatic
diseases, consequently, most of the research performed concerning TRIM21/Ro52
has been in relation to its quality as an autoantigen.  Much effort has been spent on
trying to explain why and how the intracellular TRIM21/Ro52 becomes an
autoimmune target, and if this has any importance in the etiology of Sjögren's
syndrome and congenital heart block. This thesis has a different focus; its main
purpose is to understand the biological function of TRIM21/Ro52. The discovery
of the RING domain, and the growing evidence implicating TRIM proteins in
innate antiviral responses, has renewed the interest in TRIM21/Ro52. So far,
TRIM21/Ro52 has been implicated in the regulation of cytokine expression,
binding of IgG and the regulation of the cell cycle.
The aim of this thesis is to contribute to a better understanding of the structure
and function of TRIM21/Ro52. The domains of TRIM21/Ro52 have only been
predicted; therefore, the integrity and folding of these domains need to be
determined experimentally. Furthermore, the putative role of TRIM21/Ro52 in
ubiquitination also needs experimental support and the regulation of the
intracellular localization of TRIM21/Ro52 is poorly understood. In addition to this
in vitro characterization of TRIM21/Ro52, an in vivo characterization of
TRIM21/ Ro52 is critical for a more complete understanding of its biology. For
relevant in vivo studies, one mouse strain with a disrupted TRIM21/Ro52 gene
(Ro52-/-), and two TRIM21/Ro52 transgenic (Ro52-Tg) mouse strains were
generated.
★
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RESULTS
TRIM21/Ro52 forms weak dimers and binds Zn2+
(Paper I)
The RING, B-box, coiled-coil and B30.2 domains of Ro52 are predicted based on
sequence homology with other proteins. Although sequence based predictions are
reliable, it has never been shown that the predicted domains of Ro52 adopt the
corresponding secondary structures. To investigate the secondary structure of the
predicted domains, biochemical, biophysical, and molecular biology techniques
were used.
By using limited proteolysis, it is possible to find stable secondary structure
domains of a protein. Secondary structures are less prone to proteolytic digestion
than a random coil, therefore they can be detected as non-degraded fragments after
limited proteolysis. Full-length Ro52 was expressed and purified as a maltose-
binding protein (MaBP) fusion protein. For limited proteolysis, MaBP-Ro52 was
digested with trypsin or chymotrypsin. At different time-points, the proteolysis was
stopped, and the reactions were analyzed by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE).
Two stable Ro52 fragments were identified: the RING-B-box (aa 6-121) and
coiled-coil (aa 121-260) domains. The B30.2 domain was not detected as a stable
fragment, which could be interpreted as if B30.2 is not a structurally stable domain,
or that the lack of a stable B30.2 fragment is due to the expression system used (see
discussion). For further analyzes, the identified stable fragments were expressed
and purified as 6xHis (His6) fusions proteins from the strain BL21-Gold (DE3)
pLysS.
To determine if the RING-B-box domain was stabilized by Zn2+ binding, a
limited proteolysis with trypsin was preformed in the presence or absence of Zn2+.
As detected by matrix-assisted laser desorption ionization time-of-flight mass
spectrometry (MALDI-TOF-MS), the RING-B-box was significantly stabilized by
Zn2+ but not by DNA, suggesting that RING-B-box folding is dependent on and
stabilized by Zn2+. Thus, as predicted by sequence homology, the RING-B-box
region of Ro52 is a Zn2+ binding region.
Circular dichroism (CD) was used to reveal the secondary structures of the
different Ro52 domains. The coiled-coil region had a dominating alpha-helical
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contribution, while the RING-B-box and RBCC structures had a large contribution
of beta strand structure (Fig 8).
Coiled-coil domains are often involved in oligomer formation, and to investigate
wether the coiled-coil of Ro52 contribute to oligomer formation, analytical
ultracentrifugation and a mammalian two-hybrid assay were used. A weak homo
dimerization of the coiled-coil domain was detected (KD=25 µM) by
ultracentrifugation; also, a weak oligomer formation was detected by the two-
hybrid assay.
In conclusion, the N-terminal domains of Ro52 adopt stable secondary
structures as predicted, and the RING-B-box domain is dependent on Zn2+ ions
for proper folding. Furthermore, Ro52 may form weak dimers through the coiled-
coil domain.
★
Figure 8. Secondary structures of Ro52.
(A) In contrast to the RING-B-box and
RBCC, the coiled-coil domain of Ro52 has a
distinct alpha-helical structure. (B) Contri-
bution of different structural elements to the
RBCC and coiled-coil domain. (C) Thermal
unfolding of the secondary struc-tures was
only observed for the coiled-coil domain.
A
B
C
-36-
TRIM21/Ro52 is an E3 ligase
(Paper II&III)
When the work on paper II began, it was uncertain if Ro52 was indeed an E3 ligase
as suggested by the presence of the RING domain. However, it was known that
Ro52 was ubiquitinated (Fukuda-Kamitani and Kamitani, 2002) and shortly before
the publishing of paper II it was also shown that Ro52 was an E3 ligase (Wada and
Kamitani, 2006a). In paper II the finding that Ro52 is an E3 ligase is expanded, and
in paper III, it is shown that the E3 ligase activity of Ro52 is inhibited by anti-
RING autoantibodies from patients with SS and SLE.
To investigate if Ro52 was an E3 ligase, autoubiquitination assays were used.
Autoubiquitination is a phenomenon in where E3 ligases modify themselves with
polyubiquitin chains; since this can occur in the absence of a substrate it is unclear
whether autoubiquitination is only an experimental artifact or if it also is of
physiological relevance. In any case, autoubiquitination assays are useful for
demonstrating E3 ligase activity.
A transfection based ubiquitination assay (Treier et al., 1994) was first used to
show that ubiquitination of Ro52 is RING dependent, indicative of RING
dependent autoubiquitination (paper II). FLAG tagged Ro52 (FLAG-Ro52) and
6xHis tagged ubiquitin (His6-Ub) were coexpressed in 293T cells by transfection
with the corresponding plasmids. After 48 hours, cells were lysed in a denaturing
lysis buffer, and proteins covalently modified by His6-Ub were purified using a
Ni2+-nitrilotriacetic acid (Ni-NTA) resin. His6-Ub modified proteins were separated
by SDS-PAGE followed by immunoblotting with an anti-FLAG antibody. FLAG-
Ro52 was detected as a high molecular weight smear, showing that it had been
modified by polyubiquitin. In contrast, FLAG-Ro52ΔRING was not modified by
polyubiquitin, demonstrating that that the ubiquitination of Ro52 was RING
dependent.
To ensure that Ro52 was autoubiquitinated, and to exclude that the observed
ubiquitination was dependent on another E3 ligase ubiquitinating Ro52 only in the
RING domain, an in vitro ubiquitination assay was used (Lorick et al., 1999).
Purified His6-Ro52 was mixed with E1, ubiquitin and different E2s in a reducing
Tris-buffer containing ATP and MgCl2 (paper II). After incubating at 25°C for one
hour, the reactions were terminated by the addition of Laemmli sample buffer and
boiling. The reactions were separated by SDS-PAGE followed by immunoblotting
against ubiquitin. Autoubiquitinated Ro52 was observed with several E2s.
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To investigate if the RING domain was critical for the E3 ligase activity of
Ro52, in vitro autoubiquitination assays were made using Ro52 mutants either
lacking the RING domain or with critical cysteine residues in the RING domain
mutated to alanine residues (C20A, C32A or C55A, C58A) (paper III). All these
Ro52 mutants lacked E3 ligase activity. Also, Ro52 could mediate the formation of
K48 and K63 chains as shown by using ubiquitin mutants with only one lysine
residue, K48 only and K63 only mutants.
Sera from patients with SLE and, even more so SS, frequently have high titers of
anti-Ro52 autoantibodies. These antibodies are mainly directed against dominant
epitopes in the coiled-coil region, but antibodies to the RING domain are also
detectable. To explore the possibility that anti-RING antibodies could inhibit the
E3 ligase activity of Ro52, in vitro ubiquitin assays were performed, into which
Figure 9.  Ro52 is an E3 ligase. RING dependent ubiquitination of Ro52 was
detected in cell transfection experiments (A), and autoubiquitination occurs in in
vitro autoubiquitination experiments (B-F).
A B
C D
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purified IgG fractions from different patients were added (paper III). Affinity
purified anti-RING antibodies from an anti-RING positive patient were used as a
positive control. IgG fractions from anti-RING positive patients inhibited the E3
ligase activity of Ro52, while IgG fractions from anti-RING negative patients did
not.
In all, TRIM21/Ro52 is a RING dependent E3 ligase that can use several E2
ubiquitin-conjugating enzymes and mediate the creation of both K48 and K63
polyubiquitin chains. Moreover, anti-RING autoantibodies from patients with SS
and SLE can inhibit the E3 ligase activity in vitro by binding to the RING domain.
★
TRIM21/Ro52 expression is induced by IFNα
and herpes simplex virus
(Paper II&V)
IFNα is a pleiotropic cytokine expressed mainly by hematopoeitic cells, and whose
expression is strongly induced in vivo during viral infections and in cell cultures
challenged with live or inactivated viruses. In contrast, uninfected cells produce no,
or very low amounts, of IFNα. IFNα has many antiviral effects including the
modulation of the cell cycle, induction of pro-apoptotic genes and of MHC I
expression, reviewed in (Sen, 2001).
Interestingly, many (all?) TRIM genes are induced by IFNα (Lavau et al., 1995,
Stadler et al., 1995, Chelbi-Alix et al., 1995, Der et al., 1998, Asaoka et al., 2005).
TRIMs have also been shown to be induced by IFNγ, endotoxins and viruses. In
particular, Ro52 mRNA levels are induced by IFNα (Der et al., 1998, Wang and
Campbell, 2005, Zimmerer et al., 2007, Scherbik et al., 2007), IFNγ (Rhodes et al.,
2002, Kota et al., 2006), influenza virus A (Geiss et al., 2002) and
lipopolysaccharide (LPS) (Thomas et al., 2006). To verify that Ro52 is indeed
induced by IFNα or virus, cell lines and peripheral blood mononuclear cells
(PBMCs) were exposed to IFNα and/or herpes simplex virus (HSV) and Ro52
expression was measured at both the mRNA and protein levels (Fig 10).
Patients with SS and SLE are characterized by a so-called IFN signature, in
which interferon stimulated genes (ISGs) are upregulated (Gottenberg et al., 2006,
Baechler et al., 2003, Kirou et al., 2004). This, and since IFNα could induce Ro52
expression in vitro, prompted an investigation of the expression of TRIM21/Ro52
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in SS and SLE patients. PBMCs were collected from patients, and from healthy
individuals, and the mRNA levels of Ro52 were determined by Q-RT-PCR. There
was a clear increase of Ro52 expression in patients compared to controls (Fig 11).
Figure 10. Ro52 expression is increased after exposure to IFNα. Cell
lines were exposed to IFNα2b at different concentrations (A); Ro52 was
induced up to 30-fold in Daudi and 5-fold in HeLa cells. The expression of
Ro52 peaked at 3-6 hours after IFNα2b exposure at 1000 IU/ml (B). Ro52
expression was increased at the protein level both in HeLa cells (C) and
Daudi cells (D) as determined by immunoblotting.
BA
C D
Figure 11. Ro52 expression is elevated in PBMCs from patients with SS
or SLE.  Ro52 mRNA levels in PBMCs from healthy individuals and patients
with SS or SLE were compared. Interestingly, Ro52 mRNA levels were elevated
in PBMCs from patients; probably as a consequence of the general increase in
expression of IFNα induced genes (i.e. IFNα signature).
★
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TRIM21/Ro52 inhibits cell proliferation
(Paper II)
Patients with SS and SLE have elevated Ro52 mRNA levels in PBMCs. Since these
patients also have skewed populations of lymphocytes, one possibility is that
overexpression of Ro52 affect the proliferation and differentiation of lymphocytes.
B cell populations are particularly skewed in SLE and SS as manifested by B cell
lymphopenia in SLE and decreased CD19+CD27+ frequency in SS.
To investigate the effect of Ro52 overexpression in B cells, B cell lines were
stably transfected with Ro52-GFP, Ro52ΔRING-GFP or GFP. B cells over-
expressing Ro52 had a significantly lower proliferation than Ro52ΔRING-GFP or
GFP expressing cells. Because CD40 signaling induces cell death in the A20 B cell
line, the sensitivity to CD40 mediated cell death was tested in the three stably
transfected cell lines. Cells overexpressing Ro52 were more sensitive to anti-CD40
induced cell death, than Ro52ΔRING-GFP or GFP expressing cells.
Interestingly, transgenic mice overexpressing Ro52 in B cells have a very low
expression level of the transgene; this in contrast to trangenic mice expressing
Ro52ΔRING were the expression of the transgene is high (non-submitted data).
Since this is observed in independent transgenic lines, it suggests that B cells
expressing high levels of Ro52 will proliferate slower leading to a selection and
expansion of B cells expressing low levels of Ro52.
★
TRIM21/Ro52 is translocated to the nucleus after
exposure to IFNα or nitric oxide
(Paper IV,V&VI)
The intracellular localization of Ro52 has been the focus of surprisingly much
attention; probably since it has been reported that Ro52 is located in apoptotic
blebs (Miranda-Carus et al., 2000, Lawley et al., 2000, Saegusa et al., 2002, Ohlsson
et al., 2002). According to a popular hypothesis, intracellular autoantigens (e.g.
Ro52) are modified and exposed after apoptosis leading to break of tolerance,
reviewd in (Rosen and Casciola-Rosen, 2004). The purposes of paper IV and V
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were not to investigate the exposure of Ro52 after apoptosis, but rather to
understand how and when Ro52 can translocate to the nucleus. Although Ro52 is a
cytoplasmic protein, low levels of Ro52 is detectable in the nucleus (Pourmand et
al., 1998, Ohlsson et al., 2002, Kong et al., 2007). The idea that Ro52 might be
working as a transcription factor in an analogous fashion to NFκB, i.e. in a
cytoplasma-inactive versus nucleus-active dichotomy, is unlikely since Ro52
contains no DNA binding motifs. However, a nuclear role of Ro52 might be as an
E3 ligase modifying a transcription factor (e.g. IRF-8) with K48 or K63
polyubiquitin chains. Furthermore, cytoplasmic Ro52 might have a different target
than nuclear Ro52. To investigate this, the intracellular localization of Ro52 and
two different E2 enzymes in HeLa cells were determined by staining with
antibodies or fusing the proteins to fluorescent reporter proteins.
Ro52 was found to be a cytoplasmic protein, both when staining with anti-Ro52
monoclonal antibodies and when detecting red fluorescent protein (RFP) fused
Ro52 (Ro52-RFP) after transfection. Interestingly, UBE2D1 (UbcH5a) was
cytoplasmic while UBE2E1 (UbcH6) was strictly nuclear, suggesting that Ro52
might use UbcH5a as an E2 in the cytoplasm and UbcH6 as an E2 in the nucleus.
It has previously been reported that an intact coiled-coil domain is necessary for
the cytoplasmic localization of Ro52 (Pourmand et al., 1998). The CC-2 domain
contains a putative nuclear export signal (NES) and a leucine zipper. To further
investigate what regions of Ro52 are involved in the regulation of Ro52s
intracellular localization, GFP-Ro52 and several deletion mutants of GFP-Ro52
were expressed in HeLa cells, and their intracellular localization was determined by
fluorescent microscopy. GFP-Ro52 was located in the cytoplasm, but when the
leucine zipper of Ro52 was deleted (GFP-Ro52ΔLZ) Ro52 was mainly localized in
the nucleus. To investigate if the cytoplasmic localization of Ro52 was due to
continuous nuclear export, the Exportin-1 mediated nuclear export inhibitor
leptomycin B (LMB) was added to cells transfected with GFP-Ro52. Addition of
LMB did not induce nuclear translocation of Ror52. Also, Ro52 with a mutated
putative NES (GFP-Ro52mNES) was still located in the cytoplasm. In contrast,
cyclin-B1, containing a known NES, accumulate in the nucleus after addition of
LMB.
Ro52 is detected in the nucleus of a small proportion of HeLa cells, and the
question is what triggers the translocation of Ro52 to the nucleus. Since the
expression of Ro52 is induced by IFNα it is plausible that the intracellular
localization changes as well. Therefore, HeLa cells were treated with IFNα and the
intracellular localization of Ro52 was detected by immunofluorescence using
patient sera affinity purified against Ro52 or a monoclonal anti-Ro52 antibody.
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After 24 hours, a clear nuclear accumulation of Ro52 was observed, suggesting that
Ro52 is involved in IFNα responses.
It has been reported that H2O2 induces nuclear accumulation of Ro52
(Nobuhara et al., 2007). Therefore, HeLa cells were transfected with Ro52-GFP or
GFP and treated with the nitric oxide (NO) donor diethylenetriamine NONOate
(DETA-NONOate) for 6 hours, and the intracellular localization of Ro52-GFP
and GFP was determined by fluorescence microscopy. Ro52-GFP translocated
from the cytoplasm to the nucleus after treatment with DETA-NONOate.
★
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DISCUSSION
Paper I
-Why is the B30.2 domain not stable, and what about Ro52 dimers?
After limited proteolysis of Ro52 the RING/B-box and coiled-coil domains
remained as stable fragments, however, the B30.2 domain did not. This can be
interpreted as if the B30.2 domain is not a stably folded domain; but this
interpretation goes against robust data considering the B30.2 structure (James et al.,
2007). A more likely explanation is that the apparent instability of the B30.2
domain is an artifact caused by incomplete mRNA translation. Truncated Ro52
was detected already before limited proteolysis, indicating either degradation or
uncompleted translation. Due to the large size of MaBP-Ro52, uncompleted
translation is a probable reason for the truncated B30.2 domain.  A truncated B30.2
domain would be less stable due to incomplete folding, making it susceptible to
even limited proteolysis. The prokaryotic expression system used is the likely cause
of the truncated B30.2, this due to the phenomenon of codon bias. Some codons
that are used frequently in mammals are rare in prokaryotes; therefore, the t-RNA
pool for rare codons in E. coli will be depleted when expressing Ro52, leading to
stalling of the ribosome and incomplete translation. By using E. coli strains
genetically supplemented with t-RNAs rarely used in prokaryotes, translation will
proceed, leading to a non-truncated protein. The E. coli strain TB-1 used for
expression of MaBP-Ro52 is not supplemented with rare t-RNAs, explaining the
truncated Ro52. In contrast, the production of non-truncated Ro52 is increased
when using E. coli strains enriched for rare t-RNAs (data not shown).
Together with the two-hybrid data, the ultracentrifugation experiment suggests
that Ro52 forms weak dimers through the coiled-coil domain. However, when
separating the RING-B-box domain with SDS-PAGE, a weak dimerization
product of this domain was observed after Coomassie staining as a band of
approximately 30 kDa. In the same experiment, coiled-coil dimers were, however,
not observed after Coomassie staining. Rhodes et al. and Li et al. have showed that
Ro52 forms trimers by using cross-linking experiments (Rhodes and Trowsdale,
2006, Li et al., 2007b). However, these authors did not explicitly show that the
homotypic trimerization occured through the coiled-coil domain; although Rhodes
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et al. exclude that it is mediated by the RING, B-box or B30.2 domains. The most
thorough investigation of a TRIM protein oligomerization, is by Peng et al. (Peng
et al., 2000). By using a wide array of techniques, they demonstrate that TRIM28
form homo- and hetero-oligomers. Specifically, purified TRIM28 exists in a
monomer-trimer-hexamer equilibrium.
★
Paper II
-Ro52 expression in PBMCs: High or low?
The mRNA levels of Ro52 differed in PBMCs from healthy subjects compared to
PBMCs from patients with SS and SLE. This finding is in line with the interferon
signature in SS and SLE patients, and Ro52 being an interferon stimulated gene
(paper V). In contrast to the high levels of IFNα detected in SLE patients (Kim et
al., 1987), only low levels of IFNα has been detected in sera from patients with SS
(Bave et al., 2005). This argues against that the high Ro52 levels in PBMCs from SS
patients are due to high IFNα levels. However, measurement of IFNα by ELISA
has a low reproducibility and often do not correlate with results from more
sensitive bioassays (Jabs et al., 1999, Hua et al., 2006). Moreover, an IFN signature,
and infiltrates of plasmacytoid dendritic cells in salivary glands, are present in
patients with SS (Gottenberg et al., 2006), indicating that IFNα is indeed
overexpressed in patients compare to healthy controls.
Is there a differential expression of Ro52 in PBMCs? To answer this, PBMCs
from a healthy individual were purified into T cells (CD3+), monocytes (CD14+),
and B cells (CD19+) using antibody coated magnetic beads; and the expression of
Ro52 was determined by Q-RT-PCR and immunoblotting. Paradoxically, in
CD19+ cells the Ro52 expression was high at the mRNA level but low at the
protein level. An interpretation of these data is that B cells are sensitive to high
protein levels of Ro52, as shown by lower proliferation of Ro52 overexpressing B
cell lines (paper II). The high level of Ro52 mRNA does not necessarily mean that
high levels of protein is produced, e.g., due to downregulated translation.
Furthermore, in Ro52 knock-out mice, were the deleted exons are replaced with an
internal ribosome entry site (IRES) GFP reporter cassette (Ro52-/+GFP), the Ro52
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gene is expressed at a lower level in B cells than in T cells as determined by the
GFP expression (non-submitted data).
-So, Ro52 is an E3 ligase, but what is the substrate?
As shown in paper II, Ro52 is an E3 ligase. However, this result is only based on
autoubiquitination assays. To understand the role of Ro52 in vivo it is necessary to
know the substrate of Ro52 mediated ubiquitination. Three substrates have been
suggested in the literature: p27 (Sabile et al., 2006), IRF-8 (Kong et al., 2007) and
IgG heavy chain (Takahata et al., 2007). Although p27 has been suggested as a
substrate, Ro52 was not shown to be directly involved. Sabile et al. show that Ro52
is a component of the SCFSkp2 multisubunit E3 ligase complex, but do not show
that the E3 ligase activity of Ro52 is necessary for the degradation of p27. The
strongest candidate for a substrate of Ro52 is IRF-8 as reported by Kong et al.
Direct binding of the B30.2 domain to IRF-8 was shown, as well as a Ro52
mediated ubiquitination of IRF-8 in vitro. Interestingly, the ubiquitination of IRF-8
by Ro52 did not lead to degradation of IRF-8 in the proteasome, but instead to an
activation of the transcriptional activity by IRF-8. This suggests that Ro52 modifies
IRF-8 with K63 polyubiquitin chains, in contrast to Cbl-b that targets IRF-8 for
proteasomal degradation through modiciation with K48 polyubiqutin chains
(Xiong et al., 2005).
The Fc part of the IgG1 heavy chain is clearly interacting with the B30.2
domain of Ro52, however, if this binding is of physiological relevance is less
certain. Takahata et al. suggest that the IgG1 heavy chain is a substrate of Ro52,
and that Ro52 plays a role in quality control through ERAD. However, it is not
shown explicitly that the heavy chain of IgG1 indeed is a substrate of Ro52
mediated ubiquitination. After expressing FLAG-Ro52 or FLAG-Ro52ΔRING
together with the IgG1 heavy chain in 293T cells, Takahata et al. pulled out IgG1
with protein-A beads and did immunoblotting against ubiquitin. A high molecular
smear was detected only when IgG1 heavy chain was co-expressed with FLAG-
Ro52, but not when co-expressed with FLAG-Ro52ΔRING. Takahata et al.
interpret this as a Ro52 mediated ubiquitination of IgG1 that is dependent on the
RING domain. However, it cannot be ruled out that the protein-A beads co-
purifed Ro52 through a Ro52-IgG1 interaction, and that the detected high
molecular weight ubiquitin smear is only a result of autoubiquitination of Ro52.
The identification of a substrate of an E3 ligase is a difficult task. First, an
interaction to a substrate needs to be established. By nature, these interactions are
often transient, especially if the E3 ligase mediates the degradation of the substrate.
Also, it needs to be confirmed that the interaction between the E3 ligase and the
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identified substrate leads to ubiquitination of the substrate. This is usually done
through in vitro ubiquitination assays that directly show the modification of the
substrate with ubiquitin. Furthermore, the in vivo relevance of the ubiquitination
of the substrate needs to be demonstrated. E.g., that ubiquitination leads to
degradation in the proteasome, internalization from the cell surface, or activation
of transcription factors.
Why does TRIM21/Ro52 inhibit cell proliferation?
Interestingly, the human TRIM21/Ro52 gene is located in a locus suspected of
harboring a tumor suppressor gene (Kim et al., 2000, Zhao and Bepler, 2001,
Schiebe et al., 2001, Zenklusen et al., 1995). To investigate the effect of
TRIM21/Ro52 overexpression, B cells stably transfected with Ro52 or an inactive
Ro52 mutatnt were made. B cells stably overexpressing Ro52-GFP, but not
Ro52ΔRING-GFP or GFP, had a reduced proliferation, implicating Ro52 in the
regulation of cell proliferation. Importantly, however, ectopic overexpression of
proteins may lead to erroneous conclusions, e.g. due to protein misfolding or
mislocalization. Therefore, the use of adequate controls is necessary, in this case an
inactive Ro52 mutant and GFP. One problem with the used experimental setup is
the commonly observed phenomenon of transgene silencing, which makes it
difficult to maintain stably transfected cells. Although the B cells were kept under
strong selective pressure with the antibiotic geneticin (G418), Ro52-GFP
expressing cell rapidly lost expression; this in contrast to GFP-expressing cells,
which expressed high levels of GFP even without selection pressure. Making
experiments as early as possible after the verification of stable transfected clones
solved this problem. An alternative approach is to make transient transfections,
although the interpretation of such experiments might be corrupted by uneven
transfection efficiencies. The best approach is to use an inducible expression of
Ro52 or Ro52ΔRING in vivo by using Tet-On or Tet-Off mice. Although Tet-Off
Ro52-Tg and Ro52ΔRING-Tg mice were made, the expression of the transgenes
were unfortunately not detected (data not shown).
 The mechanism whereby a high expression of Ro52 inhibited the cellular
proliferation is unclear, but might be part of an intracellular anti-proliferation
program induced by type I interferons. Signaling through CD40 is known to
induce apoptosis in many transformed cells, including some high-grade B cell
lymphomas (e.g. A20 cells) (Hess and Engelmann, 1996), but how overexpression
of Ro52 enhances this sensitivity is not clear. One mechanism could be through
the induction of apoptosis, e.g. by CD95 ligation. Contradicting reports concerning
CD40 signaling in A20 cells complicates the interpretation of the results. E.g.,
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Hollmann et al. show that anti-CD40 induced apoptosis of A20 cells is not due to
increased expression of CD95 but instead they detected activation of caspase-3
(Hollmann et al., 2002). In contrast, Benson et al. demonstrate that anti-CD40
treatment upregulates the expression of CD95 on A20 cells (Benson et al., 2006).
★
Paper III
Blocking the E3 ligase activity of TRIM21/Ro52: are anti-
RING autoantibodies really doing it?
In paper III it is demonstrated that autoantibodies against the RING domain of
Ro52, but not against the other domains, inhibit the E3 ligase activity of Ro52 in
vitro. Furthermore, it is shown that antibodies from sera of patients with SS can
penetrate HeLa cells in vitro. Although these data are robust in vitro, it is a
controversial issue whether the penetration of cells with antibodies is an in vitro
artifact or a finding of physiological relevance. Since the seminal study by Alarcon-
Segovia et al (Alarcon-Segovia et al., 1978), several research groups have shown
that antibodies can penetrate living cells and even bind intracellular targets and
inhibit enzymatic activity (Reichlin et al., 1994, Koren et al., 1995, Zack et al., 1996,
Koscec et al., 1997). All these studies are made in vitro, therefore a better way of
detecting penetrating antibodies is needed. E.g., the transgenic expression of a
GFP-fused antibody light chain in mice, would allow the tracking of antibodies
without the need for secondary reagents and fixation/permeabilization of cells.
This would drastically decrease the risk of introducing artifacts due to manipulation
of cells in vitro.
Originally, the penetration of autoantibodies into human PBMCs was suggested
to occur through fragment crystallizable (Fc) receptors (Alarcon-Segovia et al.,
1978), resulting in a focus on Fc receptors in subsequent studies. Since HeLa cells
were used in paper III, the expression of different Fc receptors was investigated
through RT-PCR. Only the MHC I like neonatal Fc receptor (FcRn) (Simister and
Mostov, 1989, Burmeister et al., 1994) was expressed (data not shown), suggesting
a mechanism whereby antibodies enter the cells by pinocytosis, and bind FcRn in
the acidic endosomes, reviewed in (Lencer and Blumberg, 2005).  Instead of being
directed into the lysosomal compartment for degradation, internalized IgG is
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protected by FcRn and is recycled to the cell membrane, or hypothectically released
into the cytoplasm. FcRn also binds strongly to albumin (Chaudhury et al., 2003),
making it possible to block IgG-FcRn binding by adding albumin. In support of an
FcRn binding mechanism, no IgG was detected in HeLa cells after blocking the
FcRn with albumin (data not shown).
The transport of IgG via an FcRn dependent mechanism mediates the transfer
of antibodies across biological membranes. After internalization of IgG and
binding to FcRn, IgG-FcRn containing endosomes fuse with cell membranes and
release IgG in a pH dependent manner. Although crossing of membranes is well
described, it is unknown if IgG can be released inside the cytoplasm. One
explanation for the reported cellular penetration of antibodies, and the binding to
intracellular antigen, is that this is an artifact likely caused by the high IgG
concentrations used in vitro. High IgG concentrations might saturate the
degradation of IgG in lysosomes causing a release of free IgG into the cytoplasm.
As mentioned earlier, one way of solving this problems is through the use of
transgenic animals expressing a GFP-fused light chain of IgG.
★
Paper IV
What keeps TRIM21/Ro52 in the cytoplasm?
TRIM21/Ro52 is mainly located in the cytoplasm, however, when detecting Ro52 by
immunofluorescence or by using fluorescent protein tags, a small amount of nuclear
Ro52 is observed. Furthermore, Ro52 is often detected in the nucleus of stressed cells
(data not shown). Together, this indicates that Ro52 can be imported to the nucleus.
One hypothesis is that Ro52 is located in the cytoplasm due to a continuous export of
Ro52 from the nucleus. This would explain the low, but detectable, levels of Ro52 in
the nucleus. After either an increased rate of import, or a decreased rate of export,
Ro52 would accumulate in the nucleus. Unfortunately, however, there is no classical
NLS or NES in Ro52. Therefore, several deletion mutants of Ro52 were analyzed with
respect to their intracellular localization in hope of finding new NLS or NES
sequences. An intact coiled-coil domain (CC2) was necessary for the cytoplasmic
localization of Ro52, and interestingly, a putative leucine rich NES was located in this
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region. We hypothesized that the NES was dependent on the nuclear export receptor
Exportin-1, which is inhibited by LMB. However, neither addition of LMB, or
mutation of the NES, lead to an accumulation of Ro52 in the nucleus. Intriguingly,
calreticulin is a nuclear export receptor that has been shown to interact with Ro52
(Holaska et al., 2001, Holaska et al., 2002, Cheng et al., 1996), potentially explaining
why LMB and ablation of the putative NES in Ro52 does not affect the nuclear
localization of Ro52. Further experimentation is needed to investigate the relationship
of Ro52 and calreticulin.
Ro52 translocates to the nucleus of HeLa cells after exposure to IFNα or NO.
Since both these molecules are inflammatory mediators, we also investigated the
intracellular localization of Ro52 in inflamed tissue. Indeed, in inflamed skin from
patients with cutaneous lupus erythematosus, Ro52 was highly expressed in the
nucleus. Futhermore, the expression of inducible nitric oxide synthetase (iNOS) was
increased, suggesting that the nuclear localization of Ro52 is caused by NO. The
nuclear import of Ro52 after exposure to IFNα or NO might be dependent on a post-
translational modification, e.g. phosphorylation or nitrosylation.
Both IFNα and NO are inducers of cell cycle arrest, and thus, one possible
explanation is that Ro52 is involved in regulating proliferation after its translocation to
the nucleus. This hypothesis could be tested in cells from Ro52-/-GFP mice, which
hypothetically would have a reduced sensitivity to IFNα and NO induced cell cycle
arrest.
★
Paper V
IFN stimulated response elements in the Ro52 promoter?
The TRIM5α promoter contains interferon stimulated response elements (ISRE)
(Asaoka et al., 2005), which recruits interferon stimulated gene factor 3 (ISGF3), a
transription factor complex consisting of signal transducer and activator of
transcription 1 and 2  (STAT1 and STAT2) and IRF-9, for review see (Brierley and
Fish, 2005). ISGF3 complexes initiate transcription of TRIM5α after IFNα
induced signaling. ISRE elements have not, however, been reported in the
proximal promoter region of TRIM21/Ro52.  On the other hand, putative ISREs
can be found by bioinformatic approaches using algorithms for finding
transcription factor binding sites. One experimental approach to find ISREs is to
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clone overlapping genomic DNA fragments upstream of TRIM21/Ro52, and
using them for reporter assays of promoter activity. By inserting genomic
fragments in front of a promoterless luciferase expression cassette, transfecting the
reporter constructs into an IFNα responsive cell line, and measuring the luciferase
luminescence after addition of IFNα, it is possible to map IFNα stimulated
promoter elements. Because TRIM21/Ro52 is induced by IFNα, and possibly also
by IFNγ and LPS, more than one type of inducible promoter element is predicted
to be present in the TRIM21/Ro52 promoter. E.g., although ISREs are partially
activated by IFNγ signaling, it is also possible that the promoter contains gamma
activation sites (GAS). Indeed, binding sites for other transcription factors have
been predicted; Gilchrist et al. used a computational approach to identify genes
regulated by activating transcription factor 3 (ATF3) after TLR4 activation of
mactophages; interestingly, TRIM21/Ro52 was among the genes to contain
putatice ATF3 and NFκB binding sites (Gilchrist et al., 2006).
Ro52, yet another antiviral TRIM?
Mammalian cells contain restriction factors that inhibit infections with retroviruses
(Nisole et al., 2005). These restriction factors are dominant, as evident by their
titration with purified viral proteins, and they act at an early stage after viral entry.
Although many TRIMs have been suggested to be antiviral restriction factors, e.g.
TRIM1 (Yap et al., 2004), TRIM5 (Stremlau et al., 2004), TRIM19 (Chelbi-Alix et
al., 1998), TRIM22 (Tissot and Mechti, 1995), TRIM25 (Gack et al., 2007b) and
TRIM28 (Wolf and Goff, 2007) only the role of TRIM5 has been widely reported.
Hypothetically, the TRIM motif is an effector motif shared by many restriction
factors, while the C-terminal domain mediates the recognition of viruses. In
support of this view, the B30.2 domains of many TRIMs contain variable loops
(Song et al., 2005), which might have been positively selected to recognize viruses.
E.g., the variable loops of the B30.2 domain of TRIM5 gene show signs of a high
degree of positive selection, judged by the high ratio of non-synonymous to
synonymous variation (Song et al., 2005).
TRIM21/Ro52 also has variable loops in the B30.2 domain, however, a virus
restricting activity for TRIM21/Ro52 has not been reported. Li et al. could not
demonstrate any antiviral activity of TRIM21/Ro52 against a number of tested
retroviruses, whereas TRIM5 inhibited most of them (Li et al., 2007b).
TRIM21/Ro52 could, however, have an antiviral activity against other viruses then
the tested ones. E.g., TRIM21/Ro52 in human PBMCs was upregulated by
inactivated HSV, indicating a role in antiviral responses. Thus, an antiviral role for
TRIM21/Ro52 has not been reported, but certainly cannot be excluded.
★
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Paper VI
Could HMGB-1 also do it?
High mobility group box 1 (HMGB-1) is a nuclear DNA binding protein that also
has a role as a proinflammatory mediator. HMGB-1 is actively secreted from cells,
or released from necrotic cells (Gardella et al., 2002, Scaffidi et al., 2002). As
demonstrated in paper VI, extracellular HMGB-1 is detected in skin lesions of
patients with cutaneous lupus erythematosus. HMGB-1, like IFNα and NO, is a
proinflammatory mediator; and by binding to receptor for advanced glycosylated
end products (RAGE), TLR-2 or TLR-4, HMGB-1 can induce the activation of
NFκB transcription factors (Kokkola et al., 2005, Park et al., 2006). Thus, addition
of HMGB-1 to cells might also lead to the nuclear translocation of Ro52.  If true,
this might mean that the intracellular localization of Ro52 is regulated by
inflammatory signals in general.
★
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HYPOTHESIS
To go further, and to design experiments that provide new data regarding the
function of TRIM21/Ro52, it is necessary to first design a hypothesis. A
hypothesis will be generated by analyzing the data presented in this thesis, together
with the data available in the literature.
First, expression analysis can give clues to the function of a protein, this by
analyzing the temporal, spatial, and quantitative aspects of gene/protein
expression. E.g., a protein that only is detected in the embryonic brain is likely to
play an important role in brain development. Similarly, a protein whose expression
is restricted to a differentiated cell type is likely to be involved in the effector
function of these differentiated cells. Secondly, by analyzing signaling pathways
leading to the activation of a protein, it is possible to make predictions of protein
function. E.g., a protein upregulated by type I IFNs, could be suspected of playing
a role in antiviral defense; either by directly interfering with viral particles, or
indirectly, by changing the cellular metabolism to hinder further spreading of a
virus. Lastly, by analyzing interaction partners, the effect on cells after
overexpression of different mutants, and the biochemical properties of a protein, it
is possible to gain functional understanding and to create a new hypothesis.
Expression of TRIM21/Ro52. Using in situ hybridization, Reymond et al.
demonstrated that TRIM21/Ro52 is ubiquitously expressed in adult and
embryonic mouse tissues (Reymond et al., 2001). In addition, all immune cells in
lymph nodes, spleen, and peripheral blood express TRIM21/Ro52 as judged by
GFP expression in Ro52-/+GFP reporter mice (non-submitted data). Interestingly,
TRIM21/Ro52 is expressed at higher levels in CD3+ cells than in CD19+ and
CD11b+ cells.
It could be argued that the ubiquitous expression of TRIM21/Ro52 goes
against a cell specific function, e.g. the regulation of IgG metabolism in B cells as
described by Takahata et al. (Takahata et al., 2007). Rather, the target of
TRIM21/Ro52 mediated ubiquitination could be expected to be a ubiquitously
expressed protein. Intriguingly, all TRIMs with reported antiviral effects i.e.,
TRIM1, TRIM5, TRIM19, TRIM22, TRIM25 and TRIM28, are also ubiquitously
expressed (Reymond et al., 2001). Thus, the ubiquitous expression of
TRIM21/Ro52 might reflect its role in an ancient innate immune defense.
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Induction of TRIM21/Ro52 expression. In paper V, TRIM21/Ro52 is shown
to be induced by IFNα and HSV. Furthermore, it has previously been
demonstrated that TRIM21/Ro52 is induced by IFNγ and LPS. The IFNα, IFNγ,
and LPS signaling pathways (Fig 12) are all involved in inflammatory responses
against infectious organisms. E.g., HSV induces interferon production by
plasmacytoid DCs (Lund et al., 2003) after activating the TLR2 and TLR9 signaling
pathways (Sato et al., 2006). Hence, it is plausible that TRIM21/Ro52 expression is
upregulated as part of a genetic program designed to fight off invading
microorganisms.
Function! Although the in vitro binding of IgG heavy chain and TRIM21/Ro52 is
robust, a physiological consequence of this interaction remains to be convincingly
demonstrated. The other proposed substrate of TRIM21/Ro52, p27, is
Fig 12. Signaling through type I IFN receptors (IFNRA1, IFNRA2), type II IFN
receptor (IFNRGα, IFNRGβ) or through TLR4 leads to an increased expression
of TRIM/Ro52; maybe as a part of an antiviral genetic program.
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ubiquitinated by the multisubunit E3 ligase complex SCFSkp2, of which
TRIM21/Ro52 has been suggested to be a subunit. In addition, TRIM21/Ro52
has been demonstrated to enhance the ubiquitination of p27 by SCFSkp2, but was
not shown to directly ubiquitinate p27. Therefore, TRIM21/Ro52 might be a
cofactor of SCFSkp2 but not a bona fide E3 ligase for p27. This, and the fact that
TRIM21/Ro52 is implicated in IFN signaling pathways, makes IRF-8 the most
attractive target since TRIM21/Ro52 is demonstrated to directly bind and
ubiquitinate IRF-8.
TRIM21/Ro52 is hypothetically a protein involved in innate immune responses
against invading microorganisms. However, like many proteins, TRIM21/Ro52
might play different roles in different cell types, even though it works through the
same intracellular mechanisms. E.g., the high expression of TRIM21/Ro52 in T
cells could mean that TRIM21/Ro52 is involved in regulating T cell responses to
infection, e.g. by regulating IFNγ or IL-2 expression. In contrast, the lower
expression in B cells indicates that TRIM21/Ro52 is inducible and might have a
different role in B cells. It would be interesting to investigate if the expression of
TRIM21/Ro52 is induced (or turned off) by some stimuli, e.g., CD3 and CD28
signaling in T cells or CD40 signaling in B cells. Cells from Ro52-/-GFP mice will be
useful in delineating the role of TRIM21/Ro52 in immunity.
In conclusion, it is likely that TRIM21/Ro52 soon will be reported to be
necessary for cellular responses against certain types of infections.
★
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CONCLUSION
Through the use of biochemical, biophysical, and molecular biological techniques,
we demonstrate that the ubiquitously expressed intracellular protein
TRIM21/Ro52 is a Zn2+ binding protein and a RING dependent E3 ligase.
Moreover, TRIM21/Ro52 was found to be overexpressed in PBMCs of patients
with SS and SLE, and ectopic overexpression of TRIM21/Ro52 in B cells in vitro
inhibited proliferation. We hypothesized that the increased TRIM21/Ro52
expression in patients is a part of the interferon signature seen in SS and SLE.
Indeed, expression of TRIM21/Ro52 was induced in cell lines and human PBMCs
in vitro after incubation with IFNα. Interestingly, TRIM21/Ro52 expression was
also induced in PBMCs after addition of inactivated herpes simplex virus,
indicating that TRIM21/Ro52 is an interferon stimulated gene that is involved in a
genetic program designed to fight infections. In addition, after incubation with
IFNα or nitric oxide, TRIM21/Ro52 was translocated from the cytoplasm to the
nucleus.
In all, TRIM21/Ro52 is an E3 ligase that inhibits cell proliferation and whose
expresssion is induced by IFNα and herpes simplex.
★
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